Gupse Adali, Elif Yorulmaz, Celal Ulasoglu, Yasar Colak, Ilyas Tuncer, Department of Gastroenterology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Doktor Erkin Caddesi Kadikoy, Istanbul 34730, Turkey.
World J Gastroenterol. 2013 Dec 21;19(47):9049-56. doi: 10.3748/wjg.v19.i47.9049.
To investigate serum insulin-like growth factor-binding protein 5 (IGFBP-5) levels and intestinal IGFBP-5 expression in patients with Crohn's disease (CD).
We analyzed the serum concentrations and intestinal expression of IGFBP-5 in 42 patients with CD, of whom 26 had endoscopically or radiologically proven stricture formation. Nine of the 42 patients had active disease, with a Crohn's disease activity index > 150. Serum IGFBP-5 levels were analyzed in 20 healthy controls matched by sex and age to the CD patients. Serum IGFBP-5 was measured using an enzyme-linked immunosorbent assay. Intestinal tissue was obtained from patients through endoscopic biopsies. IGFBP-5 expression was detected using immunohistochemistry and was scored semiquantitatively.
The median serum IGFBP-5 concentrations of CD patients were significantly lower compared with healthy controls [median 7.2 (IQR: 5.5-11.3) ng/mL vs 11.3 (8.0-44.6) ng/mL, P < 0.001]. There was no significant difference between median serum IGFBP-5 levels in CD patients with or without stricture formation [6.9 (5.5-11.3) ng/mL vs 7.8 (5.3-10.1) ng/mL, P = 0.815]. The serum IGFBP-5 levels were not significantly different between patients with active disease and inactive disease [7.2 (6.5-7.6) ng/mL vs 7.2 (5.5-11.3) ng/mL, P = 0.890]. However, a significant correlation was observed between serum IGFBP-5 levels and platelet count (PLT) (r = 0.319, P = 0.0395). No significant correlation was found between tissue IGFBP-5 immunohistochemical staining intensity scores and serum IGFBP-5 levels. No significant difference was found when comparing the serum IGFBP-5 levels among the patients with different tissue IGFBP-5 staining scores (absent/very weak, weak, moderate or strong). There was a significant correlation between tissue IGFBP-5 staining scores and white blood cell count (r = 0.391, P = 0.01) and PLT (r = 0.356, P = 0.021).
Our results indicate that serum IGFBP-5 concentrations were lower in CD patients compared to healthy controls regardless of disease activity or the presence of stricture formation.
研究克罗恩病（CD）患者血清胰岛素样生长因子结合蛋白 5（IGFBP-5）水平和肠道 IGFBP-5 表达。
我们分析了 42 例 CD 患者的血清浓度和肠道 IGFBP-5 表达，其中 26 例经内镜或影像学证实存在狭窄形成。42 例患者中有 9 例为活动期疾病，克罗恩病活动指数>150。通过与 CD 患者相匹配的性别和年龄，选择 20 名健康对照者分析血清 IGFBP-5 水平。采用酶联免疫吸附试验测定血清 IGFBP-5 水平。通过免疫组织化学检测肠道组织中 IGFBP-5 的表达，并进行半定量评分。
与健康对照组相比，CD 患者的中位血清 IGFBP-5 浓度明显较低[中位数 7.2（IQR：5.5-11.3）ng/ml 比 11.3（8.0-44.6）ng/ml，P<0.001]。有或无狭窄形成的 CD 患者的中位血清 IGFBP-5 水平无显著差异[6.9（5.5-11.3）ng/ml 比 7.8（5.3-10.1）ng/ml，P=0.815]。活动期和非活动期疾病患者的血清 IGFBP-5 水平无显著差异[7.2（6.5-7.6）ng/ml 比 7.2（5.5-11.3）ng/ml，P=0.890]。然而，血清 IGFBP-5 水平与血小板计数（PLT）呈显著正相关（r=0.319，P=0.0395）。组织 IGFBP-5 免疫组化染色强度评分与血清 IGFBP-5 水平之间无显著相关性。不同组织 IGFBP-5 染色评分（无/弱、弱、中或强）的患者之间血清 IGFBP-5 水平无显著差异。组织 IGFBP-5 染色评分与白细胞计数（r=0.391，P=0.01）和 PLT（r=0.356，P=0.021）呈显著正相关。
我们的结果表明，与健康对照组相比，CD 患者的血清 IGFBP-5 浓度无论疾病活动度或狭窄形成均较低。
